Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age–related macular degeneration: real world data from the Fight Retinal Blindness registry

被引：0
作者：
Marc Figueras-Roca
Alba Parrado-Carrillo
Vuong Nguyen
Ricardo P. Casaroli-Marano
Aina Moll-Udina
Mark C. Gillies
Daniel Barthelmes
Javier Zarranz-Ventura
机构：
[1] Institut Clínic d’Oftalmologia (ICOF),Macular Research Group, Save Sight Institute
[2] Hospital Clínic de Barcelona,Department of Ophthalmology
[3] Biomedical Research Institute August Pi i Sunyer (IDIBAPS),Department of Surgery, School of Medicine
[4] University of Sydney,undefined
[5] University Hospital Zurich and University of Zurich,undefined
[6] University of Barcelona,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2021年 / 259卷
关键词：
Neovascular age–related macular degeneration; Treat and extend; Fixed bimonthly; Electronic medical record; Benchmark standard; Naive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1463 / 1470
页数：7
相关论文
共 78 条
  • [1] Smith W(2001)Risk factors for age-related macular degeneration: pooled findings from three continents Ophthalmology. 108 697-704
  • [2] Assink J(2014)Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) Br J Ophthalmol 98 1144-1167
  • [3] Klein R(2004)Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 564-572
  • [4] Schmidt-Erfurth U(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
  • [5] Chong V(2006)Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432-1444
  • [6] Loewenstein A(2014)Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology. 121 193-201
  • [7] Friedman D(2007)An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 566-583
  • [8] O'Colmain B(2012)Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology. 119 1388-1398
  • [9] Muñoz B(2014)The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes Ophthalmology. 121 1966-1975
  • [10] Rosenfeld PJ(2016)Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol Ophthalmology 123 51-59
12345678